Compared to conventional biologics (e.g., TNF-α inhibitors and IL-17/IL-23 antagonists), which are costly, require long-term injections, and may increase infection or tumor risks.[58,59] XBT’s natural components might offer a safer profile while maintaining anti-inflammatory efficacy. The gene discussed is IL17A; the disease is infection.